Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4777073 | 0.94 | POLB (0.52) | POLBGAAJAK1HRH3MLNR | |
| Trifluoroacetic Acid SCHEMBL4775304 | 0.85 | SLC2A1 (0.43) | POLBHRH3SLC2A1ALDH1A1CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL4774899 | 0.81 | SLC2A1 (0.43) | GAAHRH3SLC2A1MLNRAXL | |
| SCHEMBL4767967 | 0.80 | HRH3 (0.48) | HRH3NPC1RAB9AALDH1A1 | |
| SCHEMBL4768406 | 0.80 | HRH3 (0.46) | HRH3RAB9AALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4766836 | 0.79 | SLC2A1 (0.44) | POLBHRH3SLC2A1AXLNPC1 | |
| Trifluoroacetic Acid SCHEMBL4764951 | 0.79 | HRH3 (0.47) | GAAHRH3SLC2A1NPC1RAB9A | |
| Trifluoroacetic Acid SCHEMBL4770952 | 0.79 | LMNA (0.51) | POLBHRH3SLC2A1AXLNPC1 | |
| Trifluoroacetic Acid SCHEMBL4775257 | 0.79 | ROCK2 (0.44) | GAAHRH3SLC2A1AXLNPC1 | |
| Trifluoroacetic Acid SCHEMBL4770476 | 0.78 | SLC2A1 (0.43) | POLBHRH3SLC2A1MLNRAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | claimed |
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | POLB 4330/4885GAA 984/4885JAK1 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.